FindTrial
Sign In

effect of alpha blockers in benign prostatic hyperplasia

A prospective study to evaluate the efficacy and adverse effects of alpha blockers in the management of benign prostatic hyperplasia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/033122
Enrollment
80
Registered
2021-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Silodosin: 8mg once daily orally for 8 weeks Intervention2: Tamsulosin: 0.4 mg once daily orally for 8 weeks

Sponsors

DR I C VIGNESH RAJA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Benign prostatic hyperplasia with international prostatic symptom score above 7 Patient on silodosin Patient on tamsulosin willing to give informed consent

Exclusion criteria

Exclusion criteria: Prostate carcinoma Patients with concomitant HIV, HBV or HCV Renal failure Liver disease Patient planned for cataract surgery. Psychiatry patients

Design outcomes

Primary

MeasureTime frame
reduction in IPSSTimepoint: 4th week 8th week—

Secondary

MeasureTime frame
adverse drug reactionsTimepoint: 4th week 8th week—

Countries

India

Contacts

Public ContactDR I C VIGNESH RAJA

DHANALAKSHMI SRINIVASAN MEDICAL COLLEGE AND HOSPITAL

sharavankumar1923@yahoo.co.in9443080854

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026